Summary
Vertex Pharmaceuticals Inc. filed an 8-K report on February 9, 2009, to disclose its consolidated financial results for the year and quarter ended December 31, 2008. The primary purpose of this filing is to provide investors with updated financial performance information. The report specifically references a press release, Exhibit 99.1, dated February 9, 2009, which contains the detailed financial results. This filing is crucial for investors seeking to understand Vertex Pharmaceuticals' financial standing as of the end of 2008. While the 8-K itself does not contain the full financial data, it serves as the official notification and incorporation of the press release containing these results. Investors are directed to review Exhibit 99.1 for comprehensive details on revenue, earnings, and other key financial metrics for the reported periods.
Key Highlights
- 1Vertex Pharmaceuticals Inc. filed an 8-K report on February 9, 2009.
- 2The report discloses consolidated financial results for the year and quarter ended December 31, 2008.
- 3Exhibit 99.1, a press release dated February 9, 2009, contains the detailed financial results.
- 4The press release is incorporated by reference into the 8-K filing.
- 5This filing informs investors about the company's financial performance as of the end of 2008.
- 6Information within Exhibit 99.1 is not deemed 'filed' for Section 18 liability purposes but is intended for investor information.